Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Lipids in Health and Disease|September 3, 2015
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialRichard L Dunbar, Stephen J Nicholls, Kevin C Maki, et al.Journal of Clinical Pharmacology|August 19, 2024
A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in ChinaJing Zhang, Guoying Cao, Yong Huo, et al.Journal of the American College of Cardiology|September 1, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled AnalysisStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.Pharmacology Research & Perspectives|October 19, 2024
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trialsStephen J Nicholls, Adam J Nelson, John J P Kastelein, et al.American Journal of Preventive Cardiology|June 15, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trialsLiffert Vogt, Michael H Davidson, Michael Szarek, et al.Journal of Clinical Lipidology|June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trialChristie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.The Journal of Prevention of Alzheimer'S Disease|October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular diseaseMichael H Davidson, Michael Szarek, Philip Scheltens, et al.Journal of Atherosclerosis and Thrombosis|April 3, 2024
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 TrialMariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, et al.Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.American Journal of Preventive Cardiology|July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experienceAdam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.Pageof 3